New sudan ebola vaccine shows promise in phase 2 trial
NCT ID NCT06036602
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new vaccine designed to protect against Sudan ebolavirus, a close relative of the Ebola virus. Researchers gave the vaccine or a placebo to 125 healthy adults to see if it is safe and triggers an immune response. The goal is to find a way to prevent this deadly disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBOLA SUDAN VIRUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KEMRI/Centre for Respiratory Disease Research Siaya Clinical Research Annex
Siaya, Kenya
-
Makerere University-Walter Reed Project
Kampala, Uganda
More trials for these conditions
Other studies related to the condition(s) this trial covers.